Abiopharma

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

Nuvalent Appoints Ron Squarer to Board of Directors

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

UTHR: Notification

Best iPhone Accessories For 2026

Best Mechanical Keyboards (2026)

Best Wireless Headphones (2026)

Best Inkjet Printers For 2026

Best Office Accessories In 2026

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach